Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355961 | 0.89 | LMNA (0.51) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL18355571 | 0.87 | LMNA (0.49) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL18356265 | 0.87 | MEN1 (0.53) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL16260534 | 0.86 | LMNA (0.48) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL29955561 | 0.86 | GAA (0.49) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL26265696 | 0.85 | MEN1 (0.51) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL15999479 | 0.84 | ALDH1A1 (0.53) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL23481519 | 0.84 | PKM (0.51) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL29952246 | 0.84 | PKM (0.51) | LMNAMAPTGAAMEN1KMT2A | |
| SCHEMBL29955877 | 0.83 | MAPT (0.45) | LMNAMAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000902-A1 | EGFR-TARGETED NANOPARTICLES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2017-01-05 | — | — | US | disclosed |
| US-9446149-B2 | Nanoparticles stabilized with nitrophenylboronic acid compositions | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160000934-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-07 | — | — | US | disclosed |
| US-9132097-B2 | Nanoparticles stabilized with nitrophenylboronic acid compositions | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000934-A1 | NANOPARTICLES STABILIZED WITH NITROPHENYLBORONIC ACID COMPOSITIONS | NCL, B3GNT2, NBAS | LMNA 653/4885MAPT 205/4885GAA 589/4885 |
| US-20170000902-A1 | EGFR-TARGETED NANOPARTICLES | EGFR, ERBB2, ERBB3 | LMNA 2532/4885MAPT 1113/4885GAA 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.